Clinical trial
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
NCT00104091 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00104091 |
|---|---|
| Title | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors |
| Official title | A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | TP-38 |
| Enrollment | 56 |
| Start date | Dec 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Feb 23, 2005 |
| Last update posted | May 23, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: